Data entry guide

Updated 05/02/25 with character limits

OD2A-LOCAL Performance Measures: Quick Reference Guide for Qualitative Data
This document serves as a Quick Reference Guide to qualitative data that will be entered into Partner’s Portal
including data for one qualitative performance measure, HE_Impact, as well as contextual and data quality questions
for all eight performance measures. All information presented in this document can be found within the OD2ALOCAL Performance Measures Technical Guidance v2. (April 2025). Additionally, this companion document can be
used alongside the Excel Reporting Tool, which will capture quantitative data on seven performance measures. All
data will be submitted to CDC within the Performance Measures Module of Partner’s Portal.

Qualitative Performance Measure: HE_Impact

HE_Impact
Reporting
Specifications

Impactful practices for improving access to care and treatment for disproportionately
affected populations
The following format is recommended for reporting this qualitative indicator:
1. Brief description of the implemented and/or tailored (adapted to specific cultural, linguistic,
environmental, or social needs of populations) evidence-based intervention or innovative practice
(including setting and whether navigators were included if applicable) and how these compare to
previous efforts. (3,000 characters)
2. How access to care or treatment has been improved, and what new/existing community assets
were leveraged. (2,000 characters)
3. Specific populations disproportionately affected by overdose and underserved with care and
treatment programs are impacted by efforts (if tracked).
4. This is optional. Any other outcomes that were improved (provides recipients the option to expand
beyond access to care and include any other outcomes, for example, retention in care, decreased
opioid use). (500 characters)
The length of the narrative should be succinct, but each impactful practice* should have a descriptive
paragraph if more than one is outlined.

Updated 05/02/25 with character limits

Contextual and Data Quality Questions
Label Name

Performance Measure

Contextual Questions

Impactful practices for
improving access to care
and treatment for
disproportionately
affected populations

1.

HE_Activities

Number of health impact
overdose prevention
interventions focused on
disproportionately
affected populations
implemented with OD2A
funding

1.

HR_Encounters

Number of harm
reduction service
encounters at
organizations funded or
supported by OD2A

1.

HE_Impact

2.

Data Quality Questions

What barriers prevent achieving access to
care and treatment for SUD? (2,000
characters)
What facilitators support achieving access to
care and treatment for SUD? (2,000
characters)

1.

Please describe the activities in this
performance measure, for whom they were
intended, and how the activities were
implemented and/or tailored (e.g.,
linguistically, culturally) for disproportionally
affected populations? (8,000 characters)

1.

What are the barriers for people accessing
harm reduction services in your jurisdiction?
(2,000 characters)
2. What are the facilitators for people accessing
harm reduction services in your jurisdiction?
(2,000 characters)
3. What types of services are included in the
encounters reported? (1,000 characters)
4. Please estimate the proportion of harm
reduction service encounters that occurred:
___% at brick-and-mortar locations
___% via mobile-based outreach services
___% via mail-based delivery
___% other (please specify)
5. (If selecting optional disaggregate), describe
who your jurisdiction serves when referring to
populations disproportionately affected by
overdose. (1,000 characters)

1.

2.

Describe any issues or
concerns that impact the
quality of the data shared
(e.g., data completeness,
data accuracy,
facilitators/barriers for
collection and reporting).
(2,000 characters)
Describe any issues or
concerns that impact the
quality of the data shared
(e.g., data completeness,
data accuracy,
facilitators/barriers for
collection and reporting).
(2,000 characters)
Describe any issues or
concerns that impact the
quality of the data shared
(e.g., data completeness,
data accuracy,
facilitators/barriers for
collection and reporting).
(2,000 characters)
How many OD2A-funded
organizations are
included in the data
submitted? (3 characters)

Updated 05/02/25 with character limits
HR_Naloxone

Number of naloxone
doses distributed by
OD2A-funded or
supported organizations

LTC_Navigators_
Hours

Number of hours
navigators spent on
linkage to care and harm
reduction services via
warm handoffs

LTC_Referrals

Number of referrals care
and harm reduction
services

1.

What are barriers to accessing or receiving
naloxone? (2,000 characters)
2. What are facilitators to accessing or receiving
naloxone? (2,000 characters)
3. How did you use OD2A Funds to distribute
naloxone (e.g., staffing to distribute, vending
machines)? (1,000 characters)
4. This contextual question is optional. Describe
mechanisms used to distribute naloxone (e.g.,
mail in, handoffs). (1,000 characters)

1.

1.

1.

How many navigators are included in this
performance measure? (3 characters)
2. Describe what types of navigators are included
in the data reported (e.g., certified peer
recovery specialists, peer support specialists,
case managers, patient navigators, community
health workers, persons with lived experience).
(3,000 characters)
3. Describe methods to support and retain
navigators, including average hourly pay,
benefits, and additional supports (e.g., trauma,
wellness, emotional/psychological support,
infrastructure such as a phone). (2,000
characters)
Types of Impactful Referrals
1. (Optional) This contextual question is optional.
If you have other OD2A funded or supported
referrals beyond referrals to MOUD, behavioral
treatment only (without MOUD), and harm
reduction services. Please describe the “other”
types of referrals. (1,000 characters)
Reporting Partners
2. Approximately, what % of healthcare facilities
(e.g., hospitals, emergency departments, and
other clinical settings) reported data to your

2.

1.

If you selected “other”
type of organizations in
the reporting tool, please
describe. (1,000
characters)
Describe any issues or
concerns that impact the
quality of the data shared
(e.g., data completeness,
data accuracy,
facilitators/barriers for
collection and reporting).
(2,000 characters)
Describe any issues or
concerns that impact the
quality of the data shared
(e.g., data completeness,
data accuracy,
facilitators/barriers for
collection and reporting).
(2,000 characters)

Describe any issues or
concerns that impact the
quality of the data shared
(e.g., data completeness,
data accuracy,
facilitators/barriers for
collection and reporting).
(2,000 characters)

Updated 05/02/25 with character limits

HS_Training

Percent of clinicians who
received training on
implementing the “2022
CDC Clinical Practice
Guideline for Prescribing
Opioids for Pain”

HS_SUD_Protocols

Number of health/clinical
settings implementing or
improving protocols
and/or policies for
evidence-based SUD
treatment or referrals

jurisdiction for this performance measure? (If
% not available, report total number of
healthcare facilities that reported)
3. Approximately, what % of EMS agencies
reported data to your jurisdiction for this
performance measure? (If % not available,
report total number of EMS agencies that
reported).
4. Approximately, what % of carceral settings
(e.g., prisons and jails), reported data to your
jurisdiction for this performance measure? (If
% not available, report total number of carceral
settings that reported).
5. Approximately, what % of harm reduction
settings (e.g., SSPs) reported data to your
jurisdiction for this performance measure? (If
% not available, report total number of carceral
settings that reported).
1. Describe the trainings including the title,
number offered, length, who conducted them,
and where the training occurred. (4,000
characters)
2. What populations are served by the clinicians
who were trained? (1,000 characters)
3. What are barriers to effectively training
clinicians on the “2022 CDC Clinical Practice
Guideline”? (2,000 characters)
4. What are facilitators to effectively training
clinicians on the “2022 CDC Clinical Practice
Guideline”? (2,000 characters)
1. Describe how access to MOUD for healthcare
settings has changed since implementing
policies or protocols. (2,000 characters)
2. Describe the partnerships for SUD referral with
the health settings included in this indicator.
What steps were taken to develop and build
the partnerships for SUD referrals? (3,000
characters)

1.

Describe any issues or
concerns that impact the
quality of the data shared
(e.g., data completeness,
data accuracy,
facilitators/barriers for
collection and reporting).
(2,000 characters)

1.

What types of health
settings are included in
the reported data? (1,000
characters)
Describe any issues or
concerns that impact the
quality of the data shared
(e.g., data completeness,

2.

Updated 05/02/25 with character limits
data accuracy,
facilitators/barriers for
collection and reporting).
(2,000 characters)